Impact of blood analysis and immune function on the prognosis of patients with COVID-19

Yue-qiang Fu; Yue-lin Sun; Si-wei Lu; Yang Yang; Yi Wang; Feng Xu

In the survival group (n = 71), after treatments of symptoms, cough, shortness of breath, and dyspnea were relieved to varying degrees, and the chest CT gradually improved. Four patients were well enough for discharge within 2 weeks after admission. The remaining hospitalized survivors (n=67) underwent blood tests, 2 weeks after treatment. Lymphocyte count and neutrophil count return to normal range in most patients. However, in 13 of the 67 surviving patients after 2 weeks of treatment, the lymphocyte count was still below the lower limit of normal (1.1 × 10 9 /L). In addition, in 4 of the 67 surviving patients after 2 weeks of treatment, the neutrophil count was above the higher limit of normal (6.3 × 10 9 /L). In 53 patients who tested cellular immunity of the survival group after 2 weeks of hospitalization, the count of lymphocyte subsets returned to normal range in most patients (Table 7) . However, in 13 of these 53 patients, the CD3+ count remained lower than the lower limit of the normal reference value (723/µL); in 10 of these 55 patients, the CD4+ count was still lower than the lower limit of the normal reference value (404/µL). . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.